| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10001966 | HBV | ENSG00000108381.11 | protein_coding | ASPA | No | No | 443 | P45381 Q6FH48 |
| TVIS10023334 | HBV | ENSG00000108381.11 | protein_coding | ASPA | No | No | 443 | P45381 Q6FH48 |
| TVIS10027718 | HBV | ENSG00000108381.11 | protein_coding | ASPA | No | No | 443 | P45381 Q6FH48 |
| TVIS10053086 | HBV | ENSG00000108381.11 | protein_coding | ASPA | No | No | 443 | P45381 Q6FH48 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ASPA |
|---|---|
| DrugBank ID | DB00128 |
| Drug Name | Aspartic acid |
| Target ID | BE0000187 |
| UniProt ID | P45381 |
| Regulation Type | |
| PubMed IDs | 17254025; 17194761; 17177147; 17219235; 17275978 |
| Citations | Wang J, Matalon R, Bhatia G, Wu G, Li H, Liu T, Lu ZH, Ledeen RW: Bimodal occurrence of aspartoacylase in myelin and cytosol of brain. J Neurochem. 2007 Apr;101(2):448-57. Epub 2007 Jan 24.@@Bitto E, Bingman CA, Wesenberg GE, McCoy JG, Phillips GN Jr: Structure of aspartoacylase, the brain enzyme impaired in Canavan disease. Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):456-61. Epub 2006 Dec 28.@@Janson CG, McPhee SW, Francis J, Shera D, Assadi M, Freese A, Hurh P, Haselgrove J, Wang DJ, Bilaniuk L, Leone P: Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI. Neuropediatrics. 2006 Aug;37(4):209-21.@@Srikanth SG, Chandrashekar HS, Nagarajan K, Jayakumar PN: Restricted diffusion in Canavan disease. Childs Nerv Syst. 2007 Apr;23(4):465-8. Epub 2007 Jan 12.@@Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM: N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol. 2007 Feb;81(2):89-131. Epub 2007 Jan 5. |
| Groups | Approved; Nutraceutical |
| Direct Classification | Aspartic acid and derivatives |
| SMILES | N[C@@H](CC(O)=O)C(O)=O |
| Pathways | Lesch-Nyhan Syndrome (LNS); Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Xanthinuria Type I; Hyperornithinemia with Gyrate Atrophy (HOGA); Purine Nucleoside Phosphorylase Deficiency; Carnosinuria, Carnosinemia; Tyrosine Metabolism; Disulfiram Action Pathway; Hyperprolinemia Type II; Glutamate Metabolism; Adenine Phosphoribosyltransferase Deficiency (APRT); Mercaptopurine Action Pathway; Argininosuccinic Aciduria; L-Arginine:Glycine Amidinotransferase Deficiency; Xanthine Dehydrogenase Deficiency (Xanthinuria); Tyrosinemia Type I; Hyperinsulinism-Hyperammonemia Syndrome; Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency); Mitochondrial DNA Depletion Syndrome; Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency; Carbamoyl Phosphate Synthetase Deficiency; Hyperprolinemia Type I; Myoadenylate Deaminase Deficiency; Homocarnosinosis; Malate-Aspartate Shuttle; Arginine and Proline Metabolism; Purine Metabolism; Gout or Kelley-Seegmiller Syndrome; Adenylosuccinate Lyase Deficiency; Ammonia Recycling |
| PharmGKB | PA448494 |
| ChEMBL | CHEMBL274323 |
